Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 1, 2004, Pages 25-33

  Kupelian, Patrick A ^a   Potters, Louis ^b   Khuntia, Deepak ^c   Ciezki, Jay P ^c   Reddy, Chandana A ^c   Reuther, Alwyn M ^c   Carlson, Thomas P ^c   Klein, Eric A ^c  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Localized prostate cancer; Radiotherapy; Relapse free survival; Surgery

Indexed keywords

ANTIGENS; DOSIMETRY; IMPLANTS (SURGICAL); STATISTICAL METHODS; TUMORS;

MULTIVARIATE ANALYSIS;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

BEAM THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FOLLOW UP; HUMAN; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RADIATION DOSE; REVIEW;

EID: 0346363495     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00784-3     Document Type: Article

References (32)

1. Holmberg L., Bill-Axelson A., Helgesen F., et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 347:2002;781-789.
2. Steineck G., Helgesen F., Adolfsson J., et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 347:2002;790-796.
3. Paulson D.F., Lin G.H., Hinshaw W., et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol. 128:1982;502-504.
4. Hanks G.E. More on the Uro-Oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 14:1988;1053-1054.
5. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 44:1999;789-799.
6. Beyer D, Nath R, Butler W, et al., for the Clinical Research Committee of the American Brachytherapy Society. American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:273-275.
7. Potters L. Permanent prostate brachytherapy Lessons learned, lessons to learn . Oncology (Huntingt). 14:2000;981-991.
8. Potters L., Perez C.A., Beyer D.C. Permanent source brachytherapy for prostate cancer ACR Appropriateness Criteria . Radiology. 215:(Suppl.): 2000;1383-1400.
9. Potters L, Cha C, Ashley R, et al. The role of external beam irradiation in patients undergoing prostate brachytherapy. Urol Oncol 2000;5:112-117.
10. Consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
11. Kupelian P.A., Elshaikh M., Reddy C.A., et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era A large single-institution experience with radical prostatectomy and external-beam radiotherapy . J Clin Oncol. 20:2002;3376-3385.
12. Kupelian P.A., Mohan D.S., Lyons J., et al. Higher than standard radiation doses (72 Gy or greater) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 46:2000;567-574.
13. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
14. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response Results of the M. D. Anderson phase III randomized trial . Int J Radiat Oncol Biol Phys. 53:2002;1097-1105.
15. Menon M., Tewari A., Divine G., et al. Comparison of long-term survival in men with clinically localized prostate cancer managed conservatively, with definitive radiation or radical prostatectomy. J Urol. 165:(Suppl.):2001;151.
16. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 95:2002;281-286.
17. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml Int J Radiat Oncol Biol Phys. 37:1997;1053-1058.
18. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
19. Beyer D.C., Brachman D.G. Failure free survival following brachytherapy alone for prostate cancer Comparison with external beam radiotherapy . Radiother Oncol. 57:2000;263-267.
20. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients Results from a single practice . Int J Radiat Oncol Biol Phys. 48:2000;111-117.
21. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
22. Polascik T.J., Pound C.R., DeWeese T.L., et al. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer A 7-year biochemical (PSA) progression analysis . Urology. 51:1998;884-890.
23. 125iodine brachytherapy for localized prostate cancer. J Urol. 161:1999;1212-1215.
24. Kupelian P.A., Buchsbaum J.C., Patel C., et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 52:2002;704-711.
25. Jhaveri F.M., Zippe C.D., Klein E.A., et al. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer 10-year results . Urology. 54:1999;884-890.
26. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 281:1999;1591-1597.
27. Iselin C.E., Robertson J.E., Paulson D.F. Radical perineal prostatectomy Oncological outcome during a 20-year period . J Urol. 161:1999;163-168.
28. Walsh P.C. Radical prostatectomy for the treatment of localized prostatic carcinoma. Urol Clin North Am. 7:1980;583-591.
29. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 317:1987;909-916.
30. Gretzer M.B., Trock B.J., Han M., et al. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol. 168: (4 Pt 1):2002;1419-1422.
31. Kattan M.W., Fearn P.A., Leibel S., et al. The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 48:2000;1469-1474.
32. Hanlon A.L., Diratzouian H., Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 53:2002;297-303.